Two Sigma Securities, LLC Regeneron Pharmaceuticals, Inc. Transaction History

Two Sigma Securities, LLC

$10.3 Billion
Q1 2024

A detailed history of Two Sigma Securities, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Securities, LLC holds 4,500 shares of REGN stock, worth $4.61 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

4,500

Previous 1,400 221.43%

Holding current value

$4.61 Million

Previous $1.23 Million 252.4%

% of portfolio

0.04%

Previous 0.01%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$775.18 - $881.7 $5.95 Million - $6.77 Million	7,681 Added 2685.66%	7,967 $7 Million
Q3 2023 Nov 14, 2023	SELL	$692.45 - $844.37 $2.97 Million - $3.62 Million	-4,287 Reduced 93.75%	286 $235,000
Q2 2023 Aug 14, 2023	SELL	$700.03 - $830.35 $1.04 Million - $1.24 Million	-1,490 Reduced 24.58%	4,573 $3.29 Million
Q1 2023 May 15, 2023	BUY	$680.49 - $826.97 $4.13 Million - $5.01 Million	6,063 New	6,063 $4.98 Million
Q3 2022 Nov 14, 2022	SELL	$573.97 - $724.32 $56,823 - $71,707	-99 Reduced 7.8%	1,171 $807,000

Q2 2022 Aug 15, 2022	SELL	$548.35 - $738.84 $2.4 Million - $3.23 Million	-4,375 Reduced 77.5%	1,270 $751,000
Q1 2022 May 16, 2022	BUY	$595.12 - $698.43 $1.81 Million - $2.12 Million	3,034 Added 116.2%	5,645 $3.94 Million
Q4 2021 Feb 14, 2022	BUY	$543.48 - $670.97 $1.01 Million - $1.24 Million	1,850 Added 243.1%	2,611 $1.65 Million
Q3 2021 Nov 15, 2021	SELL	$574.03 - $680.96 $282,996 - $335,713	-493 Reduced 39.31%	761 $461,000
Q2 2021 Aug 16, 2021	BUY	$472.8 - $558.54 $76,120 - $89,924	161 Added 14.73%	1,254 $700,000
Q1 2021 May 17, 2021	SELL	$446.73 - $548.2 $197,007 - $241,756	-441 Reduced 28.75%	1,093 $517,000
Q4 2020 Feb 16, 2021	BUY	$478.3 - $607.98 $414,207 - $526,510	866 Added 129.64%	1,534 $741,000
Q3 2020 Nov 16, 2020	SELL	$544.75 - $658.21 $3,268 - $3,949	-6 Reduced 0.89%	668 $374,000
Q2 2020 Sep 10, 2020	SELL	$493.32 - $643.92 $4.44 Million - $5.8 Million	-9,000 Reduced 93.03%	674 $420,000
Q2 2020 Aug 14, 2020	BUY	$493.32 - $643.92 $4.26 Million - $5.56 Million	8,642 Added 837.4%	9,674 $6.03 Million
Q4 2019 Feb 14, 2020	SELL	$274.13 - $376.51 $994,817 - $1.37 Million	-3,629 Reduced 77.86%	1,032 $387,000
Q3 2019 Nov 14, 2019	BUY	$273.46 - $318.39 $1.01 Million - $1.17 Million	3,680 Added 375.13%	4,661 $1.29 Million
Q2 2019 Aug 14, 2019	SELL	$299.6 - $414.82 $424,233 - $587,385	-1,416 Reduced 59.07%	981 $307,000
Q4 2018 Feb 14, 2019	SELL	$335.82 - $403.04 $1.08 Million - $1.29 Million	-3,209 Reduced 57.24%	2,397 $895,000
Q3 2018 Nov 14, 2018	SELL	$351.14 - $408.51 $238,775 - $277,786	-680 Reduced 10.82%	5,606 $2.27 Million
Q2 2018 Aug 14, 2018	BUY	$284.6 - $344.99 $913,281 - $1.11 Million	3,209 Added 104.29%	6,286 $2.17 Million
Q1 2018 May 15, 2018	BUY	$315.82 - $393.78 $685,961 - $855,290	2,172 Added 240.0%	3,077 $1.06 Million
Q4 2017 Feb 14, 2018	SELL	$358.63 - $469.95 $48,056 - $62,973	-134 Reduced 12.9%	905 $340,000
Q3 2017 Nov 14, 2017	BUY	$431.38 - $504.0 $448,203 - $523,656	1,039	1,039 $465,000

Others Institutions Holding REGN

# of Institutions

1,427

Shares Held

82.1M

Call Options Held

835K

Put Options Held

1.46M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $110B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Securities, LLC with notifications on news.

Account

Two Sigma Securities, LLC Regeneron Pharmaceuticals, Inc. Transaction History